The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2023 | Options available to patients with TP53-mutated MDS beyond stem cell transplantation
Magnus Tobiasson, MBBS, Karolinska Institute, Solna, Sweden, briefly discusses treatment options available to patients with TP53-mutated myelodysplastic syndromes (MDS) beyond stem cell transplantation (SCT), including hypomethylating agents (HMAs), venetoclax, and various checkpoint inhibitors. This interview took place at The 8th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2023), held in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
